Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Cited by (1,433)

Items 401–500 of 1,433

1. Novel Agents in Multiple Myeloma
   Raphael Elie Szalat, Nikhil C. Munshi · 2019 · The Cancer Journal
2. Monoclonal antibodies in the treatment of AL amyloidosis: co‐targetting the plasma cell clone and amyloid deposits
   Tereza Popková, Roman Hájek, Tomáš Jelı́nek · 2020 · British Journal of Haematology
3. Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis
   Zhaomeng Hou, Ping Jiang, Shaoting Su, Honghai Zhou · 2022 · Frontiers in Pharmacology
4. Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
   Arjun Lakshman, Jithma P. Abeykoon, Shaji Kunnathu Kumar, S. Vincent Rajkumar, David Dingli, Francis K. Buadi, Wilson I. Gonsalves, Nelson Leung, Angela A. Dispenzieri, Taxiarchis Kourelis et al. · 2017 · American Journal of Hematology
5. Sequencing multiple myeloma therapies with and after antibody therapies
   van de Donk, Niels W. C. J. · 2020 · Hematology
6. MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
   Sarah Brown, Debbie Sherratt, Samantha Hinsley, Louise M Flanagan, Sadie Roberts, Katrina Walker, Andrew Hall, Guy Pratt, Christina Messiou, Matthew W. Jenner et al. · 2021 · BMJ Open
7. Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
   Akihiro Kitadate, Toshiki Terao, Kentaro Narita · 2021 · Cancer Science
8. Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
   Julia Erin Wiedmeier, Peter Leif Bergsagel · 2022 · Life
9. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
   Pieter Sonneveld, Sonja Zweegman, Michèle Cavo, Kazem Nasserinejad, Annemiek Broijl, Rosella Troia, Luděk Pour, Sandra Croockewit, Paolo Corradini, Francesca F. Patriarca et al. · 2022 · HemaSphere
10. Triplet vs. doublet drug regimens for managing multiple myeloma
    Massimo Offidani, Laura Corvatta, Silvia Gentili · 2017 · Expert Opinion on Pharmacotherapy
11. Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
    Concetta Conticello, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Giuseppe Sapienza, Valerio Leotta, Marina Silvia Parisi, Uroš Markovic, Bruno Garibaldi et al. · 2019 · Journal of Clinical Medicine
12. Approach to the Adult Acute Lymphoblastic Leukemia Patient
    Valentina Sas, Vlad Moisoiu, Patric Teodorescu, Sebastian Trancă, Laura Pop, Sabina Iluta, Sergiu Paşca, Cristina Lucia Blag, Sorin Claudiu Man, Andrei Roman et al. · 2019 · Journal of Clinical Medicine
13. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
    Rahul Kumar Banerjee, Yelak Biru, Craig Emmitt Cole, Beth M Faiman, Shonali Midha, Sikander Ailawadhi · 2024 · Blood Cancer Journal
14. Novel targets for the treatment of relapsing multiple myeloma
    Nicola Giuliani, Fabrizio Accardi, Valentina Marchica, Benedetta Dalla Palma, Paola Storti, Denise Toscani, Emanuela Vicario, Fabio Malavasi · 2019 · Expert Review of Hematology
15. Salvage second transplantation in relapsed multiple myeloma
    Binod Dhakal, Anita D’Souza, Ariel Kleman, Saurabh Chhabra, Meera Mohan, Parameswaran Hari · 2020 · Leukemia
16. Immunotherapeutic and Targeted Approaches in Multiple Myeloma
    Omar Nadeem, Yu‐Tzu Tai, Kenneth Carl Anderson · 2020 · ImmunoTargets and Therapy
17. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
    Jiye Liu, Teru Hideshima, Lijie Xing, Su Wang, Wenrong Zhou, Mehmet Samur, Tomasz Sewastianik, Daisuke Ogiya, Gang An, Shaobing Gao et al. · 2021 · Science Advances
18. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options
    Baptiste Le Calvez, Philippe Moreau, Cyrille Touzeau · 2021 · Expert Opinion on Investigational Drugs
19. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
    Noemí Puig, Juan A Flores-Montero, Leire Burgos, María‐Teresa Cedena, Lourdes Cordón, José-Juan Pérez, Luzalba Sanoja-Flores, Irene Manrique, Paula Rodríguez‐Otero, Laura Rosiñol et al. · 2021 · Cancers
20. The real-world outcomes of multiple myeloma patients treated with daratumumab
    Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen et al. · 2021 · PLoS ONE
21. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
    Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen S Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, Patrick Lefèbvre, Adriana Rossi · 2021 · BMC Cancer
22. CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment
    Audrey Abecassis, Nathalie Roders, Maxime Fayon et al. · 2022 · eJHaem
23. Mechanisms of Resistance in Multiple Myeloma
    Athanasios Papadas, Fotis A. Asimakopoulos · 2017 · Handbook of experimental pharmacology
24. Ixazomib: a novel drug for multiple myeloma
    Saurabh Zanwar, Jithma P. Abeykoon, Prashant Kapoor · 2018 · Expert Review of Hematology
25. Collaborative Physician-Pharmacist–Managed Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays
    Karen I. Sweiss, Scott M Wirth, Lisa K. Sharp, Irene Park, Helen Sweiss, Damiano Rondelli, Pritesh Rajni Patel · 2018 · Journal of Oncology Practice
26. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
    Samer Tabchi, Rajit Nair, Chutima Kunacheewa, Krina K. Patel, Hans Chulhee Lee, Sheeba K. Thomas, Behrang Amini, Sairah Ahmed, Rohtesh S. Mehta, Qaiser Bashir et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
27. Molecular dynamics of targeting CD38 in multiple myeloma
    Fabio Malavasi, Angelo Corso Faini, Fabio Morandi, Barbara Castella, Danny Incarnato, Salvatore Oliviero, Alberto L. Horenstein, Massimo Massaia, Niels W.C.J. van de Donk, Paul Gerard Guy Richardson · 2021 · British Journal of Haematology
28. Targeting CD38 in Antibody-Mediated Rejection
    Katharina A. Mayer, Klemens Budde, Matthias Diebold, Philip F. Halloran, Georg A. Böhmig · 2025 · Transplant International
29. Gammapatías monoclonales de significado renal
    Fernando Caravaca‐Fontán, Eduardo Gutiérrez, Ramón Delgado Lillo, Manuel Praga · 2017 · Nefrología
30. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
    Aleksander Salomon‐Perzyński, Adam Walter‐Croneck, Lidia Usnarska‐Zubkiewicz, Dominik Dytfeld, Patrycja Zielińska, Małgorzata Wojciechowska, Jadwiga Hołojda, Pawel J. Robak, Anna Pasternak, Wanda Knopińska‐Posłuszny et al. · 2019 · Advances in Medical Sciences
31. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor
    Reeder M. Robinson, Leticia Reyes, Ravyn M. Duncan, Haiyan Bian, Eric D. Strobel, Sarah L. Hyman, Allen B. Reitz, Nathan G. Dolloff · 2019 · European Journal of Medicinal Chemistry
32. Immunotherapy for Multiple Myeloma
    Hideto Tamura, Mariko Ishibashi, Mika Sunakawa, Koiti Inokuchi · 2019 · Cancers
33. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy
    Mary‐Elizabeth M. Percival, Ryan C. Lynch, Anna B. Halpern et al. · 2020 · JCO Oncology Practice
34. Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
    Mattia D’Agostino, Salvatore Innorcia, Mario Boccadoro, Sara Bringhen · 2020 · International Journal of Molecular Sciences
35. Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
    Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert, Bogusław Machaliński · 2023 · Cancers
36. Transfusion management for patients taking an anti-CD38 monoclonal antibody
    Carolina Bonet Bub, Isabel Nagle Reis, Maria Giselda Aravechia, Leandro Dinalli Santos, Eduardo Peres Bastos, José Mauro Kutner, Lilian Maria Castilho · 2017 · Hematology Transfusion and Cell Therapy
37. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
    Rimke Oostvogels, Margot Jak, Reinier A P Raymakers, Rogier Mous, Monique C. Minnema · 2018 · British Journal of Haematology
38. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
    Joseph R Mikhael, Judith B. Manola, Amylou Constance Dueck, Suzanne R. Hayman, Kurt R. Oettel, Abraham Sebastian Kanate, Sagar Lonial, S. Vincent Rajkumar · 2018 · Blood Cancer Journal
39. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
    Massimo Vincenzo Martino, Marco Rossi, Anna Ferreri, Barbara Loteta, Antonella Morabito, Tiziana Moscato, Giuseppe Console, Vanessa Innao, Virginia Naso, Pasquale Fabio Provenzano et al. · 2019 · Expert Review of Hematology
40. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
    Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Ishida, Tadao, Yamamoto, Junichi, Ito, Takumi, Futami, Muneyoshi, Ri, Masaki et al. · 2021 · Journal of Experimental & Clinical Cancer Research
41. Managing multiple myeloma in elderly patients
    Evan Diamond, Oscar Boutros Lahoud, Heather Jolie Landau · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
42. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
    Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Christina Weisel, María‐Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Ellen Reece, Paula Rodríguez‐Otero et al. · 2025 · Blood
43. Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
    Xianwu Luo, Xueqing Du, Jie-Li Li, Xiaoping Liu, Xiangyu Meng · 2018 · Cancer Management and Research
44. Progression with clinical features is associated with worse subsequent survival in multiple myeloma
    Rajshekhar Chakraborty, Hien D. Liu, Lisa A Rybicki, Jacqulyn Tomer, Jack Khouri, Robert M. Dean, Beth M Faiman, Matt E Kalaycio, Christy Joy Samaras, Navneet S. Majhail et al. · 2019 · American Journal of Hematology
45. Daratumumab in dialysis-dependent multiple myeloma
    Preethi Jeyaraman, Alka Bhasin, Nitin Dayal · 2020 · Blood Research
46. Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021
    Ivo Demel, Juli Bago, Roman Hájek, Tomáš Jelı́nek · 2020 · British Journal of Haematology
47. CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
    Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, Renée Poels, Ruud W. J. Ruiter, Jyoti Naik, Huipin Yuan, Joost Dick de Bruijn, Niels W.C.J. van de Donk, Sonja Zweegman et al. · 2021 · HemaSphere
48. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
    Sahar Kassem, Béré Diallo, Nizar El-Murr, Nadège Carrié, Alexandre Tang, Alain Fournier, Hélène Bonnevaux, Céline Nicolazzi, Marine Cuisinier, Isabelle Reguigne-Arnould et al. · 2022 · Blood
49. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
    Sonia Morè, Massimo Offidani, Laura Corvatta, Maria Teresa Petrucci, Francesca Fazio · 2023 · Cancers
50. CD 38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy
    Jiří Minařík, Martin Novák, Patrik Flódr, Jana Balcárková, Miroslava Mlynárčiková, Petra Krhovská, Tomáš Pika, Zuzana Pikalová, Jaroslav Bačovský, Vlastimil Ščudla · 2017 · European Journal Of Haematology
51. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Andrzej J. Jakubowiak, Ivan Houisse, Istvan Matyas Majer, Ágnes Benedict, Marco Campioni, Sumeet S. Panjabi, Sikander Ailawadhi · 2017 · Expert Review of Hematology
52. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
    Daryl Chen Lung Tan, Jae Hoon Lee, Wen-Ming Chen, Kazuyuki Shimizu, Jian Hou, Kenshi Suzuki, Weerasak Nawarawong, Shang‐Yi Huang, Chor Sang Chim, Kihyun Kım et al. · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
53. The start of a new wave: Developments in proteasome inhibition in multiple myeloma
    Kwee Yong, Sebastian Gonzalez‐McQuire, Zsolt Roland Szabó, Paul Schoen, Roman Hájek · 2018 · European Journal Of Haematology
54. Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma
    Janna L. Huskey, Raymond L. Heilman, Hasan A. Khamash, Rafaël Fonseca · 2018 · Transplantation
55. Current Development of Monoclonal Antibodies in Cancer Therapy
    Sagun Parakh, Dylan King, Hui Kong Gan, Andrew Mark Scott · 2019 · Recent results in cancer research/Recent Results in Cancer Research
56. Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
    James C. Ackley, Miguel Armenta Ochoa, Delta Ghoshal, Krishnendu Roy, Sagar Lonial, Lawrence Boise · 2021 · Cancers
57. T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment
    Niels W.C.J. van de Donk, Leo Rasche, Surbhi Sidana, Sonja Zweegman, Alfred L. Garfall · 2024 · Blood Cancer Discovery
58. Multiple Myeloma: What Do We Do About Immunodeficiency?
    Linrong Li, Liang Wang · 2019 · Journal of Cancer
59. High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
    Alexandra Gomez-Arteaga, Tomer Martin Mark, Danielle Guarneri, Paul J. Christos, Usama S. Gergis, June Greenberg, Jingmei Hsu, Sebastian Alexander Mayer, Rubén Niesvizky, Roger Niles Pearse et al. · 2019 · Bone Marrow Transplantation
60. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
    Serika D. Naicker, Claire L. Feerick, Kevin Lynch, Dawn Swan, Cian McEllistrim, Robert B. Henderson, Niamh A. Leonard, Oliver Treacy, Alessandro Natoni, Athina Rigalou et al. · 2021 · OncoImmunology
61. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
    Hiroko Nishida · 2021 · Cancers
62. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Katja Christina Weisel, Thomas G. Martin, Amrita Y. Krishnan, Sundar Jagannath, Anil Londhe, Sandhya C. Nair, Joris Diels, Martin Vogel, Jordan Mark Schecter, Arnob Banerjee et al. · 2021 · Clinical Drug Investigation
63. Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
    Arleigh B. Robertson McCurdy, Hira S. Mian, Richard LeBlanc, Victor Hugo Jimenez-Zepeda, Jiandong Su, Esther Masih‐Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell J. White et al. · 2023 · Blood Cancer Journal
64. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
    Camille Grandclément, Carole Estoppey, E. Dheilly, Maria S. Panagopoulou, Thierry Monney, Cyrille Dreyfus, Jérémy Loyau, Valentina Labanca, Adam C.B. Drake, S. De Angelis et al. · 2024 · Nature Communications
65. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Torben Plesner, Niels W.C.J. van de Donk, Paul Gerard Guy Richardson · 2020 · Cells
66. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
    Yael Chava Cohen, Hila Magen, Noa Lavi, Moshe E. Gatt, Evgeni Chubar, Nethanel A. Horowitz, Natalia Kreiniz, Tamar Tadmor, Svetlana Trestman, Roy Vitkon et al. · 2020 · Annals of Hematology
67. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression
    Zachary J. Walker, Michael J. VanWyngarden, Brett M. Stevens, Diana Abbott, Andrew Hammes, Christophe J. Langouët-Astrié, Clayton A. Smith, Brent E. Palmer, Peter A. Forsberg, Tomer Martin Mark et al. · 2020 · Blood Advances
68. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
    Mashhour Hosny, Christie P.M. Verkleij, Jort van der Schans, Kristine A. Frerichs, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk · 2021 · Journal of Clinical Medicine
69. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
    Kiss, Szabolcs, Gede, Noémi, Hegyi, Péter, Nagy, Bettina, Deák, Rita, Dembrovszky, Fanni, Bunduc, Stefania, Erőss, Bálint, Leiner, Tamás, Szakács, Zsolt et al. · 2021 · Scientific Reports
70. Multiple Myeloma Unpacked
    Francesca Gay, Edoardo Marchetti, Giuseppe Bertuglia · 2025 · Hematological Oncology
71. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
    Elena Zamagni, Paola Tacchetti, Lucia Pantani, Michèle Cavo · 2018 · Expert Review of Hematology
72. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
    Daniel M. Feinberg, Barry A. Paul, Yubin Kang · 2019 · Cellular Immunology
73. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
    Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Meletios Athanasios Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier P Leleu et al. · 2021 · American Journal of Hematology
74. Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
    Salem J. Almaani, Samir V. Parikh, Anjali A. Satoskar · 2021 · Kidney International Reports
75. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
    Jean‐Samuel Boudreault, Cyrille Touzeau, Philippe Moreau · 2017 · Expert Review of Hematology
76. Current Review on High-Risk Multiple Myeloma
    Henry Siu Him Chan, Christine I. Chen, Donna Ellen Reece · 2017 · Current Hematologic Malignancy Reports
77. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma
    Damian J. Green, David G. Maloney, Barry E. Storer, Brenda M. Sandmaier, Leona A. Holmberg, Pamela Sue Becker, Min Fang, Paul J. Martin, George E. Georges, Michelle E. Bouvier et al. · 2017 · Blood Advances
78. The challenges of checkpoint inhibition in the treatment of multiple myeloma
    Barry A. Paul, Shuqi Kang, Zhihong Zheng, Yubin Kang · 2018 · Cellular Immunology
79. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
    Kristine A. Frerichs, Patricia W.C. Bosman, Inger S. Nijhof, Sonja Zweegman, Niels W.C.J. van de Donk · 2018 · Clinical Lymphoma Myeloma & Leukemia
80. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma
    Manisha Bhutani, David Foureau, Qing Zhang et al. · 2018 · Transplantation and Cellular Therapy
81. CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
    Kristine A. Frerichs, Christie P.M. Verkleij, Patricia W.C. Bosman, Sonja Zweegman, Henny G. Otten, Niels W.C.J. van de Donk · 2019 · Journal of Translational Autoimmunity
82. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
    Saad Z. Usmani, Chatchada Karanes, William Bensinger, Anita D’Souza, Noopur S Raje, Sascha Alexander Tuchman, Douglas Weston Sborov, Jacob P. Laubach, Giada Bianchi, Dheepak Kanagavel et al. · 2021 · Leukemia
83. Recent Advances in the Treatment and Supportive Care of POEMS Syndrome
    Maroun Bou Zerdan, Tracy I. George, Silvia Tse Bunting, Chakra P. Chaulagain · 2022 · Journal of Clinical Medicine
84. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
    Charlotte Pawlyn, Fredrik Hellem Schjesvold, David Allan Cairns, Lee‐Jen Wei, Faith E. Davies, Omar Nadeem, Haifaa Abdulhaq, María‐Victoria Mateos, Jacob P. Laubach, Katja Christina Weisel et al. · 2024 · Blood Cancer Journal
85. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab
    Xiu Yan Jiang, Joanne M. Luider, Afshin Shameli · 2019 · Cytometry Part B Clinical Cytometry
86. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
    Jorge Julio Castillo, Edward N Libby, Stephen M Ansell, M Lia Palomba, Kirsten Meid, Catherine A Flynn, Carly Leventoff, Christopher B Hergott, Tomasz Sewastianik, Elizabeth A Morgan et al. · 2020 · PubMed Central
87. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
    Meletios Athanasios Dimopoulos, Fredrik Hellem Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier P Leleu, Yolanda González Montes, Karthik Ramasamy, Alessandra Pompa, Mark‐David Levin et al. · 2022 · Blood Cancer Journal
88. Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment
    Qinchen Xu, Xiaoyan Liu, Ghazal Mohseni, Xiaodong Hao, Yidan Ren, Yi‐Wei Xu, Huiru Gao, Qin Wang, Yunshan Wang · 2022 · Cancer Cell International
89. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma
    Yun Kyoung Ryu, Edd Ricker, Craig R. Soderquist · 2022 · Journal of Clinical Medicine
90. Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
    Muhamed Baljević, Cristina Gasparetto, Gary John Schiller et al. · 2022 · eJHaem
91. Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma
    Blandine Pouleau, Carole Estoppey, Perrine Suere, Emilie Nallet, Amélie Laurendon, Thierry Monney, Daniela Pais Ferreira, Adam C.B. Drake, Laura Carretero-Iglesia, Julie Macoin et al. · 2023 · Blood
92. New Developments in Myeloma Treatment and Response Assessment
    Françoise Kraeber‐Bodéré, Bastien Jamet, Davide Bezzi, Elena Zamagni, Philippe Moreau, Cristina Nanni · 2023 · Journal of Nuclear Medicine
93. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma
    Ankit K. Dutta, Duncan R. Hewett, J. Lynn Fink, John P. Grady, Andrew C.W. Zannettino · 2017 · British Journal of Haematology
94. Safety of ixazomib for the treatment of multiple myeloma
    Antoine Bonnet, Philippe Moreau · 2017 · Expert Opinion on Drug Safety
95. ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING
    Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko · 2018 · Mediterranean Journal of Hematology and Infectious Diseases
96. Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist
    Tanya Marya Wildes, Kenneth Carl Anderson · 2018 · Hematology
97. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
    Saurabh Zanwar, Jithma P. Abeykoon, Prashant Kapoor · 2019 · Current Hematologic Malignancy Reports
98. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
    Felicitas Hitz, Marianne Kraus, Thomas Pabst et al. · 2019 · Blood Cancer Journal
99. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses
    Pellegrino Musto, Francesco La Rocca · 2020 · Expert Review of Hematology
100. Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
     Guido Lancman, Katleen S. Lozada, Nida Athar, Samantha E. Jacobs, John T. Doucette, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia